Blanket Purchase Agreement 36F79721D0169-36E79721A0023
Award Date
9/30/21
Last Date to Order
9/29/25
Federal Agency
National Acquisition Center
Awardee
Regeneron Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Regeneron Pharmaceuticals Inc. for the base year plus four option periods with a potential value of $780,000. The BPA utilizes the Pharmaceuticals and Drugs Federal Supply Schedule and has no set-aside designated. The agreement facilitates the procurement of the drugs Arcalyst and Evkeeza to support the Department of Veterans Affairs' medical programs. Arcalyst treats recurrent...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Provention Bio Inc., a biopharmaceutical company, to provide the drug TZIELD. The single-award BPA has a ceiling value of $1,444,167.20 and a period of performance from January 2023 through July 2023. This BPA was issued against Provention Bio's 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals and...
The key products and services being delivered under this Federal Supply Schedule (FSS) contract IDV awarded to Regeneron Pharmaceuticals Inc. are pharmaceuticals and drugs, with a focus on the drug EVKEEZA. The contract has a ceiling value of $2,260,000,000 and an ultimate completion date of May 31, 2026. Over time, Regeneron has expanded its services from supplying specific pharmaceutical products to providing large-scale production of therapeutics, including for national emergencies such as...
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Genzyme Corporation, doing business as Sanofi Genzyme. The BPA has a ceiling value of $3,000,000 and a period of performance from June 6, 2024 to June 5, 2026. The purpose of the BPA is to provide the VA with a streamlined contracting method to procure specialty pharmaceutical products,...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Genentech USA, Inc. for the procurement of Evrysdi. The BPA has a potential value of $1 million and a period of performance from March 12, 2021 through September 14, 2023, with four one-year option periods. The BPA was established against the Pharmaceuticals and Drugs GSA Schedule and provides a contracting vehicle for ordering Evrysdi to treat spinal muscular atrophy. Spinal muscular...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to CSL Behring L.L.C., a global biotherapeutics company that provides specialty pharmaceutical products to the VA. The BPA has a ceiling value of $17,500,000 and allows VA facilities nationwide to efficiently order the medication HAEGARDA, a C1 inhibitor treatment for hereditary angioedema, as needed through September 2025. The VA Greater Los Angeles Healthcare System...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer, to provide critical medications for the treatment of rare diseases such as pulmonary arterial hypertension. The $118.5 million BPA covers the period from August 2024 to August 2025 and allows the VA, Federal Bureau of Prisons, and other federal agencies to procure specialized drug therapies like...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the U.S. federal government, to Takeda Pharmaceuticals America Inc., a foreign-owned, for-profit manufacturer of specialized pharmaceutical products. The BPA, valued at $131,039,520.00, is a single-award contract that falls under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule. It enables the procurement of various critical medications such as CINRYZE,...
This Blanket Purchase Agreement (BPA) is a federal contract Indefinite Delivery Vehicle (IDV) awarded by the National Acquisition Center, a civilian agency, to Merck Sharp & Dohme LLC, doing business as Merck. The BPA has a ceiling value of $15,000,000 and an ultimate completion date of August 8, 2025. It was awarded on August 9, 2022 and is not set-aside. The primary purpose of this BPA is the procurement of the pharmaceutical product Welireg (belzutifan) from Merck, a major...